The role of oxidized low-density lipoproteins in atherosclerosis: The myths and the facts

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Maiolino, Giuseppe ^a   Rossitto, Giacomo ^a   Caielli, Paola ^a   Bisogni, Valeria ^a   Rossi, Gian Paolo ^a   Calò, Lorenzo A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PROBUCOL; RETINOL; SELENIUM; ZINC; LOW DENSITY LIPOPROTEIN;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL LINE; CELL PROLIFERATION; CELL STIMULATION; CELL TRANSFORMATION; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM CELL; FOAM CELL; HEART INFARCTION; HUMAN; IN VIVO STUDY; INTIMA; MACROPHAGE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; ANIMAL; CHEMISTRY; CHEMOTAXIS; CYTOLOGY; METABOLISM; NECROSIS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; CELL PROLIFERATION; CHEMOTAXIS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MONOCYTES; MYOCYTES, SMOOTH MUSCLE; NECROSIS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TUNICA INTIMA;

EID: 84886490131     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/714653     Document Type: Review

References (135)

1. Libby P., Ridker P. M., Hansson G. K., Progress and challenges in translating the biology of atherosclerosis. Nature 2011 473 7347 317 325 2-s2.0-79956319051 10.1038/nature10146
2. Majesky M. W., Developmental basis of vascular smooth muscle diversity. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 6 1248 1258 2-s2.0-34249289023 10.1161/ATVBAHA.107.141069 (Pubitemid 46809412)
3. Gimbrone M. A. Jr., Topper J. N., Nagel T., Anderson K. R., Garcia-Cardeña G., Endothelial dysfunction, hemodynamic forces, and atherogenesis. Annals of the New York Academy of Sciences 2000 902 230 240 2-s2.0-0034085698 (Pubitemid 30389128)
4. Tabas I., Williams K. J., Borén J., Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007 116 16 1832 1844 2-s2.0-37349021003 10.1161/CIRCULATIONAHA.106.676890 (Pubitemid 350287108)
5. Skålén K., Gustafsson M., Knutsen Rydberg E., Hultén L. M., Wiklund O., Innerarity T. L., Boren J., Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002 417 6890 750 754 2-s2.0-0037071843 10.1038/nature00804 (Pubitemid 34640629)
6. Navab M., Berliner J. A., Watson A. D., Hama S. Y., Territo M. C., Lusis A. J., Shih D. M., Van Lenten B. J., Frank J. S., Demer L. L., Edwards P. A., Fogelman A. M., The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff memorial lecture. Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 7 831 842 2-s2.0-8944258922 (Pubitemid 26234980)
7. Berliner J. A., Territo M. C., Sevanian A., Ramin S., Jeong Ai Kim J. A. K., Bamshad B., Esterson M., Fogelman A. M., Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. Journal of Clinical Investigation 1990 85 4 1260 1266 2-s2.0-0025359852 (Pubitemid 20123772)
8. Choi S.-H., Harkewicz R., Lee J. H., Boullier A., Almazan F., Li A. C., Witztum J. L., Bae Y. S., Miller Y. I., Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circulation Research 2009 104 12 1355 1363 2-s2.0-67650266902 10.1161/CIRCRESAHA.108.192880
9. Miller Y. I., Viriyakosol S., Worrall D. S., Boullier A., Butler S., Witztum J. L., Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 6 1213 1219 2-s2.0-20144385204 10.1161/01.ATV.0000159891.73193.31 (Pubitemid 40776611)
10. Bae Y. S., Lee J. H., Choi S. H., Kim S., Almazan F., Witztum J. L., Miller Y. I., Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circulation Research 2009 104 2 210 218 2-s2.0-59849086158 10.1161/CIRCRESAHA.108.181040
11. Parhami F., Fang Z. T., Fogelman A. M., Andalibi A., Territo M. C., Berliner J. A., Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. Journal of Clinical Investigation 1993 92 1 471 478 2-s2.0-0027170699 (Pubitemid 23209031)
12. Henriksen T., Mahoney E. M., Steinberg D., Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proceedings of the National Academy of Sciences of the United States of America 1981 78 10 I 6499 6503 2-s2.0-0019812319 (Pubitemid 12179740)
13. Tabas I., Macrophage death and defective inflammation resolution in atherosclerosis. Nature Reviews Immunology 2010 10 1 36 46 2-s2.0-72949116358 10.1038/nri2675
14. Ambrose J. A., Tannenbaum M. A., Alexopoulos D., Hjemdahl-Monsen C. E., Leavy J., Weiss M., Borrico S., Gorlin R., Fuster V., Angiographic progression of coronary artery disease and the development of myocardial infarction. Journal of the American College of Cardiology 1988 12 1 56 62 2-s2.0-0023930139
15. Little W. C., Constantinescu M., Applegate R. J., Kutcher M. A., Burrows M. T., Kahl F. R., Santamore W. P., Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988 78 5 I 1157 1166 2-s2.0-0023722916
16. Virmani R., Kolodgie F. D., Burke A. P., Farb A., Schwartz S. M., Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 5 1262 1275 2-s2.0-0034019601 (Pubitemid 30262927)
17. Stone G. W., Maehara A., Lansky A. J., De Bruyne B., Cristea E., Mintz G. S., Mehran R., McPherson J., Farhat N., Marso S. P., Parise H., Templin B., White R., Zhang Z., Serruys P. W., A prospective natural-history study of coronary atherosclerosis. New England Journal of Medicine 2011 364 3 226 235 2-s2.0-78751652694 10.1056/NEJMoa1002358
18. Libby P., Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. Journal of Lipid Research 2009 50 S352 S357 2-s2.0-66349137052 10.1194/jlr.R800099-JLR200
19. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L., Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New England Journal of Medicine 1989 320 14 915 924 2-s2.0-0024603895 (Pubitemid 19101597)
20. Steinbrecher U. P., Parthasarathy S., Leake D. S., Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proceedings of the National Academy of Sciences of the United States of America 1984 81 12 I 3883 3887 2-s2.0-0000061171 (Pubitemid 14087823)
21. Henriksen T., Mahoney E. M., Steinberg D., Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis 1983 3 2 149 159 2-s2.0-0020519662 (Pubitemid 13136501)
22. Heinecke J. W., Rosen H., Chait A., Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. Journal of Clinical Investigation 1984 74 5 1890 1894 2-s2.0-0021721459 (Pubitemid 15214102)
23. Kruth H. S., Jones N. L., Huang W., Zhao B., Ishii I., Chang J., Combs C. A., Malide D., Zhang W.-Y., Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. Journal of Biological Chemistry 2005 280 3 2352 2360 2-s2.0-12544258729 10.1074/jbc.M407167200
24. Glass C. K., Witztum J. L., Atherosclerosis: the road ahead. Cell 2001 104 4 503 516 2-s2.0-0035936802 10.1016/S0092-8674(01)00238-0 (Pubitemid 32201946)
25. Cyrus T., Witztum J. L., Rader D. J., Tangirala R., Fazio S., Linton M. F., Funk C. D., Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. Journal of Clinical Investigation 1999 103 11 1597 1604 2-s2.0-0032752579
26. Yla-Herttuala S., Rosenfeld M. E., Parthasarathy S., Glass C. K., Sigal E., Witztum J. L., Steinberg D., Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proceedings of the National Academy of Sciences of the United States of America 1990 87 18 6959 6963 2-s2.0-0025076921
27. Rankin S. M., Parthasarathy S., Steinberg D., Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. Journal of Lipid Research 1991 32 3 449 456 2-s2.0-0025756633
28. Sendobry S. M., Cornicelli J. A., Welch K., Bocan T., Tait B., Trivedi B. K., Colbry N., Dyer R. D., Feinmark S. J., Daugherty A., Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. British Journal of Pharmacology 1997 120 7 1199 1206 2-s2.0-8244253670 10.1038/sj.bjp.0701007 (Pubitemid 27149668)
29. Bocan T. M. A., Rosebury W. S., Mueller S. B., Kuchera S., Welch K., Daugherty A., Cornicelli J. A., A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis 1998 136 203 216 (Pubitemid 28133408)
30. Daugherty A., Dunn J. L., Rateri D. L., Heinecke J. W., Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. Journal of Clinical Investigation 1994 94 1 437 444 2-s2.0-0028292033 (Pubitemid 24218123)
31. Podrez E. A., Febbraio M., Sheibani N., Schmitt D., Silverstein R. L., Hajjar D. P., Cohen P. A., Frazier W. A., Hoff H. F., Hazen S. L., Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. Journal of Clinical Investigation 2000 105 1095 1108 (Pubitemid 30217694)
32. Wang Z., Nicholls S. J., Rodriguez E. R., Kummu O., Hörkkö S., Barnard J., Reynolds W. F., Topol E. J., DiDonato J. A., Hazen S. L., Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nature Medicine 2007 13 10 1176 1184 2-s2.0-34948834705 10.1038/nm1637 (Pubitemid 47530630)
33. Goldstein J. L., Ho Y. K., Basu S. K., Brown M. S., Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proceedings of the National Academy of Sciences of the United States of America 1979 76 1 333 337 2-s2.0-0009627006 (Pubitemid 9110191)
34. Quinn M. T., Parthasarathy S., Steinberg D., Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proceedings of the National Academy of Sciences of the United States of America 1988 85 8 2805 2809 2-s2.0-0001096583
35. Frostegard J., Haegerstrand A., Gidlund M., Nilsson J., Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991 90 2-3 119 126 2-s2.0-0025949134 10.1016/0021-9150(91) 90106-D
36. Cominacini L., Garbin U., Pasini A. F., Davoli A., Campagnola M., Contessi G. B., Pastorino A. M., Lo Cascio V., Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radical Biology and Medicine 1996 22 1-2 117 127 2-s2.0-0029909002 10.1016/S0891-5849(96)00271-7 (Pubitemid 26399317)
37. Yui S., Sasaki T., Miyazaki A., Horiuchi S., Yamazaki M., Induction of murine macrophage growth by modified LDLs. Arteriosclerosis and Thrombosis 1993 13 3 331 337 2-s2.0-0027411116 (Pubitemid 23075620)
38. Quinn M. T., Parthasarathy S., Fong L. G., Steinberg D., Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proceedings of the National Academy of Sciences of the United States of America 1987 84 9 2995 2998 2-s2.0-0023192020 (Pubitemid 17064764)
39. Stiko-Rahm A., Hultgardh-Nilsson A., Regnstrom J., Hamsten A., Nilsson J., Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arteriosclerosis and Thrombosis 1992 12 9 1099 1109 2-s2.0-0026649199
40. Kohno M., Yokokawa K., Yasunari K., Minami M., Kano H., Hanehira T., Yoshikawa J., Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 1998 98 4 353 359 2-s2.0-0032575301 (Pubitemid 28348058)
41. Kim J. G., Taylor W. R., Parthasarathy S., Demonstration of the presence of lipid peroxide-modified proteins in human atherosclerotic lesions using a novel lipid peroxide-modified anti-peptide antibody. Atherosclerosis 1999 143 2 335 340 2-s2.0-0032949195 10.1016/S0021-9150(98)00320-7 (Pubitemid 29166914)
42. Lindner V., Lappi D. A., Baird A., Majack R. A., Reidy M. A., Role of basic fibroblast growth factor in vascular lesion formation. Circulation Research 1991 68 1 106 113 2-s2.0-0026020827
43. Jimi S., Saku K., Uesugi N., Sakata N., Takebayashi S., Oxidized low density lipoprotein stimulates collagen production in cultured arterial smooth muscle cells. Atherosclerosis 1995 116 1 15 26 2-s2.0-0029040972 10.1016/0021-9150(95)05515-X
44. Rajavashisth T. B., Liao J. K., Galis Z. S., Tripathi S., Laufs U., Tripathi J., Chai N.-N., Xu X.-P., Jovinge S., Shah P. K., Libby P., Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. Journal of Biological Chemistry 1999 274 17 11924 11929 2-s2.0-0033597123 10.1074/jbc.274.17.11924 (Pubitemid 29197861)
45. Xu X.-P., Meisel S. R., Ong J. M., Kaul S., Cercek B., Rajavashisth T. B., Sharifi B., Shah P. K., Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999 99 8 993 998 2-s2.0-0033514984 (Pubitemid 29104486)
46. Loidl A., Claus R., Ingolic E., Deigner H.-P., Hermetter A., Role of ceramide in activation of stress-associated MAP kinases by minimally modified LDL in vascular smooth muscle cells. Biochimica et Biophysica Acta 2004 1690 2 150 158 2-s2.0-4644286379 10.1016/j.bbadis.2004.06.003 (Pubitemid 39299193)
47. Schwartz C. J., Valente A. J., Sprague E. A., Kelley J. L., Nerem R. M., The pathogenesis of atherosclerosis: an overview. Clinical Cardiology 1991 14 2 1 16 2-s2.0-0026026486
48. Cathcart M. K., Morel D. W., Chisolm G. M. III, Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. Journal of Leukocyte Biology 1985 38 2 341 350 2-s2.0-0021933648 (Pubitemid 15243435)
49. Sata M., Walsh K., Oxidized LDL activates Fas-mediated endothelial cell apoptosis. Journal of Clinical Investigation 1998 102 9 1682 1689 2-s2.0-0032211819 (Pubitemid 28516253)
50. Hardwick S. J., Hegyi L., Clare K., Apoptosis in human monocyte-macrophages exposed to oxidized low density lipoprotein. Journal of Pathology 1996 179 294 302 (Pubitemid 26266409)
51. Thorin E., Hamilton C. A., Dominiczak M. H., Reid J. L., Chronic exposure of cultured bovine endothelial cells to oxidized LDL abolishes prostacyclin release. Arteriosclerosis and Thrombosis 1994 14 3 453 459 2-s2.0-0028265694
52. Li L.-X., Chen J.-X., Liao D.-F., Yu L., Probucol inhibits oxidized-low density lipoprotein-induced adhesion of monocytes to endothelial cells by reducing P-selectin synthesis in vitro. Endothelium 1998 6 1 1 8 2-s2.0-0031751295 (Pubitemid 28490870)
53. Armstrong D. A., Oxidized LDL, ceroid, and prostaglandin metabolism in human atherosclerosis. Medical Hypotheses 1992 38 3 244 248 2-s2.0-0026651233 10.1016/0306-9877(92)90103-J
54. Kugiyama K., Sakamoto T., Misumi I., Sugiyama S., Ohgushi M., Ogawa H., Horiguchi M., Yasue H., Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circulation Research 1993 73 2 335 343 2-s2.0-0027291105 (Pubitemid 23212113)
55. Gräfe M., Auch-Schwelk W., Hertel H., Terbeek D., Steinheider G., Loebe M., Fleck E., Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL. Atherosclerosis 1998 137 1 87 95 2-s2.0-0032478226 10.1016/S0021-9150(97)00258-X (Pubitemid 28175380)
56. Allison B. A., Nilsson L., Karpe F., Hamsten A., Eriksson P., Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 5 1354 1360 2-s2.0-0032912640 (Pubitemid 29227658)
57. Liao J. K., Wee Soo Shin W. S. S., Wen Yee Lee W. Y. L., Clark S. L., Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. Journal of Biological Chemistry 1995 270 1 319 324 2-s2.0-0028821643 10.1074/jbc.270.1.319
58. Boulanger C. M., Tanner F. C., Bea M.-L., Hahn A. W. A., Werner A., Luscher T. F., Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circulation Research 1992 70 6 1191 1197 2-s2.0-0026534718
59. Harats D., Shaish A., George J., Mulkins M., Kurihara H., Levkovitz H., Sigal E., Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 9 2100 2105 2-s2.0-0033812812
60. Shen J., Herderick E., Cornhill J. F., Zsigmond E., Kim H.-S., Kühn H., Guevara N. V., Chan L., Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. Journal of Clinical Investigation 1996 98 10 2201 2208 2-s2.0-0029829533 (Pubitemid 26394192)
61. Cyrus T., Praticò D., Zhao L., Witztum J. L., Rader D. J., Rokach J., FitzGerald G. A., Funk C. D., Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001 103 18 2277 2282 2-s2.0-0035826892 (Pubitemid 32433718)
62. George J., Afek A., Shaish A., Levkovitz H., Bloom N., Cyrus T., Zhao L., Funk C. D., Sigal E., Harats D., 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 2001 104 14 1646 1650 2-s2.0-0035797843 (Pubitemid 32947528)
63. Zhao L., Cuff C. A., Moss E., Wille U., Cyrus T., Klein E. A., Praticò D., Rader D. J., Hunter C. A., Puré E., Funk C. D., Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. Journal of Biological Chemistry 2002 277 38 35350 35356 2-s2.0-0037144594 10.1074/jbc.M205738200
64. Huo H., Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004 110 2024 2031 2-s2.0-8544281676 10.1161/01.CIR.0000149088.58961.0C (Pubitemid 39492016)
65. Merched A. J., Ko K., Gotlinger K. H., Serhan C. N., Chan L., Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB Journal 2008 22 10 3595 3606 2-s2.0-54049137639 10.1096/fj.08-112201
66. Kunjathoor V. V., Febbraio M., Podrez E. A., Moore K. J., Andersson L., Koehn S., Rhee J. S., Silverstein R., Hoff H. F., Freeman M. W., Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. Journal of Biological Chemistry 2002 277 51 49982 49988 2-s2.0-0346037268 10.1074/jbc.M209649200 (Pubitemid 36014449)
67. Febbraio M., Podrez E. A., Smith J. D., Hajjar D. P., Hazen S. L., Hoff H. F., Sharma K., Silverstein R. L., Targeted disruption of the class B, scavenger receptor CD36 protects against atherosclerotic lesion development in mice. Journal of Clinical Investigation 2000 105 8 1049 1056 2-s2.0-0034101821 (Pubitemid 30217689)
68. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., Ueda O., Sakaguchi H., Higashi T., Suzuki T., Takashima Y., Kawabe Y., Cynshi O., Wada Y., Honda M., Kurihara H., Aburatani H., Doi T., Matsumoto A., Azuma S., Noda T., Toyoda Y., Itakura H., Yazaki Y., Horiuchi S., Takahashi K., Kruijt J. K., Van Berkel T. J. C., Steinbrecher U. P., Ishibashi S., Maeda N., Gordon S., Kodama T., A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997 386 6622 292 296 2-s2.0-0030895048 10.1038/386292a0 (Pubitemid 27142516)
69. Moore K. J., Kunjathoor V. V., Koehn S. L., Manning J. J., Tseng A. A., Silver J. M., McKee M., Freeman M. W., Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. Journal of Clinical Investigation 2005 115 8 2192 2201 2-s2.0-23644435612 10.1172/JCI24061 (Pubitemid 41134161)
70. Witztum J. L., You are right too! Journal of Clinical Investigation 2005 115 8 2072 2075 2-s2.0-23644458916 10.1172/JCI26130 (Pubitemid 41134146)
71. Witztum J. L., Steinberg D., The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends in Cardiovascular Medicine 2001 11 3-4 93 102 2-s2.0-0035176943 10.1016/S1050-1738(01)00111-6 (Pubitemid 33070331)
72. Praticò D., Tangirala R. K., Rader D. J., Rokach J., Fitzgerald G. A., Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nature Medicine 1998 4 10 1189 1192 2-s2.0-0031752607 10.1038/2685 (Pubitemid 28468835)
73. Erkkilä A. T., Närvänen O., Lehto S., Uusitupa M. I. J., Ylä-Herttuala S., Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 1 204 209 2-s2.0-0343048974 (Pubitemid 30048365)
74. Inoue T., Uchida T., Kamishirado H., Takayanagi K., Hayashi T., Morooka S., Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. Journal of the American College of Cardiology 2001 37 3 775 779 2-s2.0-0035281469 10.1016/S0735-1097(00)01199-2 (Pubitemid 32202444)
75. Tsimikas S., Measures of oxidative stress. Clinics in Laboratory Medicine 2006 26 3 571 590 2-s2.0-33748153794 10.1016/j.cll.2006.06.004 (Pubitemid 44308368)
76. Strobel N. A., Fassett R. G., Marsh S. A., Coombes J. S., Oxidative stress biomarkers as predictors of cardiovascular disease. International Journal of Cardiology 2011 147 2 191 201 2-s2.0-79951958873 10.1016/j.ijcard.2010.08. 008
77. Nishi K., Itabe H., Uno M., Kitazato K. T., Horiguchi H., Shinno K., Nagahiro S., Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 10 1649 1654 2-s2.0-0036791482 10.1161/01.ATV.0000033829.14012.18
78. Tsimikas S., Brilakis E. S., Miller E. R., McConnell J. P., Lennon R. J., Kornman K. S., Witztum J. L., Berger P. B., Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. New England Journal of Medicine 2005 353 1 46 57 2-s2.0-21444447949 10.1056/NEJMoa043175 (Pubitemid 41007806)
79. Rossi G. P., Cesari M., De Toni R., Zanchetta M., Maiolino G., Pedon L., Ganzaroli C., Maiolino P., Pessina A. C., Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation 2003 108 20 2467 2472 2-s2.0-0344825223 10.1161/01.CIR.0000097122.19430.48 (Pubitemid 37444407)
80. Tsimikas S., Brilakis E. S., Lennon R. J., Miller E. R., Witztum J. L., McConnell J. P., Kornman K. S., Berger P. B., Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. Journal of Lipid Research 2007 48 2 425 433 2-s2.0-33846859569 10.1194/jlr.M600361-JLR200 (Pubitemid 46220609)
81. Maiolino G., Pedon L., Cesari M., Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. International Journal of Cardiology 2013 10.1016/j.ijcard.2012.09.165
82. Röhrig B., Du Prel J.-B., Wachtlin D., Blettner M., Types of study in medical research-part 3 of a series on evaluation of scientific publications. Deutsches Arzteblatt 2009 106 15 262 268 2-s2.0-68949148906 10.3238/arztebl.2009.0262
83. Tsutsui T., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Ohnishi M., Kinoshita M., Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. Journal of the American College of Cardiology 2002 39 6 957 962 2-s2.0-0037139247 10.1016/S0735-1097(02)01721-7 (Pubitemid 34234116)
84. Shoji T., Fukumoto M., Kimoto E., Shinohara K., Emoto M., Tahara H., Koyama H., Ishimura E., Nakatani T., Miki T., Tsujimoto Y., Tabata T., Nishizawa Y., Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney International 2002 62 6 2230 2237 2-s2.0-18744366906 10.1046/j.1523-1755.2002.00692.x (Pubitemid 35366180)
85. Bayés B., Cruz Pastor M., Bonal J., Juncà J., Hernandez J. M., Riutort N., Foraster A., Romero R., Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrology Dialysis Transplantation 2003 18 1 106 112 2-s2.0-12244307891 10.1093/ndt/18.1.106 (Pubitemid 36104485)
86. Bayés B., Pastor M. C., Bonal J., Foraster A., Romero R., Oxidative stress, inflammation and cardiovascular mortality in haemodialysis-role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrology Dialysis Transplantation 2006 21 4 984 990 2-s2.0-33645284688 10.1093/ndt/gfi294
87. Shimada K., Mokuno H., Matsunaga E., Miyazaki T., Sumiyoshi K., Miyauchi K., Daida H., Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004 174 2 343 347 2-s2.0-2342513375 10.1016/j.atherosclerosis. 2004.01.029 (Pubitemid 38597092)
88. Wallenfeldt K., Fagerberg B., Wikstrand J., Hulthe J., Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. Journal of Internal Medicine 2004 256 5 413 420 2-s2.0-7244220166 10.1111/j.1365-2796.2004.01402.x (Pubitemid 39434378)
89. Naruko T., Ueda M., Ehara S., Itoh A., Haze K., Shirai N., Ikura Y., Ohsawa M., Itabe H., Kobayashi Y., Yamagishi H., Yoshiyama M., Yoshikawa J., Becker A. E., Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 4 877 883 2-s2.0-33646693817 10.1161/01.ATV.0000209886.31510.7f (Pubitemid 43732166)
90. Tsimikas S., Kiechl S., Willeit J., Mayr M., Miller E. R., Kronenberg F., Xu Q., Bergmark C., Weger S., Oberhollenzer F., Witztum J. L., Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the bruneck study. Journal of the American College of Cardiology 2006 47 11 2219 2228 2-s2.0-33646902155 10.1016/j.jacc.2006.03.001 (Pubitemid 43795077)
91. Johnston N., Jernberg T., Lagerqvist B., Siegbahn A., Wallentin L., Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. International Journal of Cardiology 2006 113 2 167 173 2-s2.0-33750460629 10.1016/j.ijcard.2005.11.006 (Pubitemid 44648400)
92. Kiechl S., Willeit J., Mayr M., Viehweider B., Oberhollenzer M., Kronenberg F., Wiedermann C. J., Oberthaler S., Xu Q., Witztum J. L., Tsimikas S., Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 Activity, and 10-year cardiovascular outcomes: prospective results from the bruneck study. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 8 1788 1795 2-s2.0-34547627109 10.1161/ATVBAHA.107.145805 (Pubitemid 47207175)
93. Lopes-Virella M. F., Hunt K. J., Baker N. L., The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis 2012 224 526 531
94. Tsimikas S., Willeit P., Willeit J., Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. Journal of the American College of Cardiology 2012 60 2218 2229
95. Holvoet P., Kritchevsky S. B., Tracy R. P., Mertens A., Rubin S. M., Butler J., Goodpaster B., Harriss T. B., The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004 53 4 1068 1073 2-s2.0-1842527452 10.2337/diabetes.53.4.1068 (Pubitemid 38436620)
96. Uusitupa M. I. J., Niskanen L., Luoma J., Vilja P., Mercuri M., Rauramaa R., Ylä-Herttuala S., Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 10 1236 1242 2-s2.0-0029819268 (Pubitemid 26339710)
97. Erkkilä A. T., Närvänen O., Lehto S., Uusitupa M. I. J., Ylä-Herttuala S., Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease. Atherosclerosis 2005 183 1 157 162 2-s2.0-26244462107 10.1016/j.atherosclerosis.2005.02.026 (Pubitemid 41416834)
98. Braun S., Ndrepepa G., Von Beckerath N., Mehilli J., Gorchakova O., Vogt W., Schömig A., Kastrati A., Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. American Heart Journal 2005 150 3 550 556 2-s2.0-24944494049 10.1016/j.ahj.2004.10.008 (Pubitemid 41317628)
99. Wilson P. W. F., Ben-Yehuda O., McNamara J., Massaro J., Witztum J., Reaven P. D., Autoantibodies to oxidized LDL and cardiovascular risk. The Framingham Offspring Study. Atherosclerosis 2006 189 2 364 368 2-s2.0-33750991054 10.1016/j.atherosclerosis.2005.12.013 (Pubitemid 44740294)
100. Mayr M., Kiechl S., Tsimikas S., Miller E., Sheldon J., Willeit J., Witztum J. L., Xu Q., Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. Journal of the American College of Cardiology 2006 47 12 2436 2443 2-s2.0-33744969769 10.1016/j.jacc.2006.03.024 (Pubitemid 43866376)
101. Lee Y. K., Lee D. H., Kim J. K., Lysophosphatidylcholine, oxidized low-density lipoprotein and cardiovascular disease in korean hemodialysis patients: analysis at 5 years of follow-up. Journal of Korean Medical Science 2013 28 268 273
102. Higgins J. P. T., Green S., Cochrane Handbook for Systematic Reviews of Interventions 2011 version 5.1.0 The Cochrane Collaboration
103. Grimes D. A., Schulz K. F., Bias and causal associations in observational research. The Lancet 2002 359 9302 248 252 2-s2.0-0037132876 10.1016/S0140-6736(02)07451-2 (Pubitemid 34113828)
104. Rochon P. A., Gurwitz J. H., Sykora K., Reader's guide to critical appraisal of cohort studies-1. Role and design. British Medical Journal 2005 330 7496 895 897 2-s2.0-17244369871 (Pubitemid 40545694)
105. George J., Harats D., Bakshi E., Adler Y., Levy Y., Gilburd B., Shoenfeld Y., Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunology Letters 1999 68 2-3 263 266 2-s2.0-0033152282 10.1016/S0165-2478(99) 00050-4 (Pubitemid 29301886)
106. Stephens N. G., Parsons A., Schofield P. M., Kelly F., Cheeseman K., Mitchinson M. J., Brown M. J., Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). The Lancet 1996 347 9004 781 786 2-s2.0-0029925181 10.1016/S0140-6736(96)90866-1 (Pubitemid 26091640)
107. Lee I.-M., Cook N. R., Gaziano J. M., Gordon D., Ridker P. M., Manson J. E., Hennekens C. H., Buring J. E., Vitamin E in the primary prevention of cardiovascular disease and cancer. The women's health study: a randomized controlled trial. Journal of the American Medical Association 2005 294 1 56 65 2-s2.0-21444438990 10.1001/jama.294.1.56 (Pubitemid 41002839)
108. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., Knecht A., Weissgarten Y., Brunner D., Fainaru M., Green M. S., Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. The Lancet 2000 356 9237 1213 1218 2-s2.0-0034619027
109. Tepel M., Van der Giet M., Statz M., Jankowski J., Zidek W., The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003 107 7 992 995 2-s2.0-0037465546 10.1161/01.CIR.0000050628.11305.30 (Pubitemid 36258722)
110. Milman U., Blum S., Shapira C., Aronson D., Miller-Lotan R., Anbinder Y., Alshiek J., Bennett L., Kostenko M., Landau M., Keidar S., Levy Y., Khemlin A., Radan A., Levy A. P., Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 2 341 347 2-s2.0-38549138535 10.1161/ATVBAHA.107.153965 (Pubitemid 351161209)
111. Virtamo J., Rapola J. M., Ripatti S., Heinonen O. P., Taylor P. R., Albanes D., Huttunen J. K., Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Archives of Internal Medicine 1998 158 6 668 675 2-s2.0-0032559780 10.1001/archinte.158.6.668 (Pubitemid 28144826)
112. Rapola J. M., Virtamo J., Ripatti S., Huttunen J. K., Albanes D., Taylor
113. Brown B. G., Zhao X.-Q., Chait A., Fisher L. D., Cheung M. C., Morse J. S., Dowdy A. A., Marino E. K., Bolson E. L., Alaupovic P., Frohlich J., Serafini L., Huss-Frechette E., Wang S., DeAngelis D., Dodek A., Albers J. J., Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine 2001 345 22 1583 1592 2-s2.0-0035969564 10.1056/NEJMoa011090 (Pubitemid 33126837)
114. Sesso H. D., Buring J. E., Christen W. G., Kurth T., Belanger C., MacFadyen J., Bubes V., Manson J. E., Glynn R. J., Gaziano J. M., Vitamins E and C in the prevention of cardiovascular disease in men: the physicians' health study II randomized controlled trial. Journal of the American Medical Association 2008 300 18 2123 2133 2-s2.0-56149111693 10.1001/jama.2008.600
115. Cook N. R., Albert C. M., Gaziano J. M., Zaharris E., MacFadyen J., Danielson E., Buring J. E., Manson J. E., A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the women's antioxidant cardiovascular study. Archives of Internal Medicine 2007 167 15 1610 1618 2-s2.0-34548040480 10.1001/archinte.167.15.1610 (Pubitemid 47280341)
116. de Gaetano G., Collaborative Group of the Primary Prevention Project, Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. collaborative group of the primary prevention project. The Lancet 2001 357 89 95
117. GISSI-Prevenzione Investigators, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico. The Lancet 1999 354 447 455
118. Greenberg E. R., Baron J. A., Karagas M. R., Stukel T. A., Nierenberg D. W., Stevens M. M., Mandel J. S., Haile R. W., Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. Journal of the American Medical Association 1996 275 9 699 703 2-s2.0-0030071655 10.1001/jama.275.9.699 (Pubitemid 26073278)
119. Hennekens C. H., Buring J. E., Manson J. E., Stampfer M., Rosner B., Cook N. R., Belanger C., Lamotte F., Gaziano J. M., Ridker P. M., Willett W., Peto R., Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. New England Journal of Medicine 1996 334 18 1145 1149 2-s2.0-0345157579 10.1056/NEJM199605023341801 (Pubitemid 26137972)
120. Hercberg S., Galan P., Preziosi P., Bertrais S., Mennen L., Malvy D., Roussel A.-M., Favier A., Briançon S., The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Archives of Internal Medicine 2004 164 21 2335 2342 2-s2.0-1842574410 10.1001/archinte.164.21.2335 (Pubitemid 39532244)
121. Collins R., Armitage J., Parish S., Sleight P., Peto R., MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet 2002 360 9326 23 33 2-s2.0-0037031094 10.1016/S0140-6736(02)09328-5 (Pubitemid 34756488)
122. Lonn E., Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. Journal of the American Medical Association 2005 293 11 1338 1347 2-s2.0-20044383911 10.1001/jama.293.11.1338 (Pubitemid 40381486)
123. Mark S. D., Wang W., Fraumeni J. F. Jr., Li J.-Y., Taylor P. R., Wang G.-Q., Guo W., Dawsey S. M., Li B., Blot W. J., Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian nutrition intervention trial. American Journal of Epidemiology 1996 143 7 658 664 2-s2.0-13344269001 (Pubitemid 26111079)
124. Omenn G. S., Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R., Glass A., Keogh J. P., Meyskens F. L. Jr., Valanis B., Williams J. H. Jr., Barnhart S., Hammar S., Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New England Journal of Medicine 1996 334 18 1150 1155 2-s2.0-9244262406 10.1056/NEJM199605023341802 (Pubitemid 26137973)
125. Waters D. D., Alderman E. L., Hsia J., Howard B. V., Cobb F. R., Rogers W. J., Ouyang P., Thompson P., Tardif J. C., Higginson L., Bittner V., Steffes M., Gordon D. J., Proschan M., Younes N., Verter J. I., Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. Journal of the American Medical Association 2002 288 19 2432 2440 2-s2.0-0037145833 10.1001/jama.288.19.2432 (Pubitemid 35340539)
126. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P., Vitamin E supplementation and cardiovascular events in high-risk patients. the heart outcomes prevention evaluation study investigators. New England Journal of Medicine 2000 342 154 160 (Pubitemid 30051646)
127. Ye Z., Song H., Antioxidant vitamins intake and the risk of coronary heart disease: meta-analysis of cohort studies. European Journal of Cardiovascular Prevention and Rehabilitation 2008 15 1 26 34 2-s2.0-39349104016 10.1097/HJR.0b013e3282f11f95 (Pubitemid 351263251)
128. Vivekananthan D. P., Penn M. S., Sapp S. K., Hsu A., Topol E. J., Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. The Lancet 2004 361 2017 2023
129. Steinhubl S. R., Why have antioxidants failed in clinical trials? American Journal of Cardiology 2008 101 10 S14 S19 2-s2.0-43049180323 10.1016/j.amjcard.2008.02.003
130. Ziouzenkova O., Asatryan L., Tetta C., Wratten M. L., Hwang J., Sevanian A., Oxidative stress during ex vivo hemodialysis of blood is decreased by a novel hemolipodialysis procedure utilizing antioxidants. Free Radical Biology and Medicine 2002 33 2 248 258 2-s2.0-0037098874 10.1016/S0891-5849(02)00875-4 (Pubitemid 34775196)
131. Sevanian A., Asatryan L., LDL modification during hemodialysis markers for oxidative stress. Contributions to Nephrology 2002 137 386 395 2-s2.0-0036051872
132. Calò L. A., Naso A., Pagnin E., Davis P. A., Castoro M., Corradin R., Riegler P., Cascone C., Huber W., Piccoli A., Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis-a molecular biological approach. Clinical Nephrology 2004 62 5 355 361 2-s2.0-8344242221 (Pubitemid 39480842)
133. Calò L. A., Naso A., D'Angelo A., Pagnin E., Zanardo M., Puato M., Rebeschini M., Landini S., Feriani M., Perego A., Malagoli A., Zagatti R., Calzavara P., Cascone C., Davis P. A., Molecular biology-based assessment of vitamin E-coated dialyzer effects on oxidative stress, inflammation, and vascular remodeling. Artificial Organs 2011 35 2 E33 E39 2-s2.0-79951634059 10.1111/j.1525-1594.2010.01125.x
134. Levy A. P., Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacology and Therapeutics 2006 112 2 501 512 2-s2.0-33749262658 10.1016/j.pharmthera.2006.05.002 (Pubitemid 44486413)
135. Blum S., Milman U., Shapira C., Miller-Lotan R., Bennett L., Kostenko M., Landau M., Keidar S., Levy Y., Khemlin A., Radan A., Levy A. P., Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 3 e18 e20 2-s2.0-40749088915 10.1161/ATVBAHA.107.159905